Oncolinx (Boston, MA) is developing the next generation of antibody-drug conjugates (ADCs)–powerful, targeted cancer therapies that are more effective and have dramatically fewer side effects than current methods of cancer treatment.

Website : https://www.oncolinx.com/

Call 2018

The 2018 call for applications for the Young Enterprise Initiative – Start in France is now closed for Finnish, Italian, South Korean, Taiwanese, and U.S. companies. The call will open soon for South African companies.

Country Programs



Receive notifications about the YEi Start in France program (Call for applications, announcement of the laureates, YEi events, etc.)

Social Links